Company intelligence / Profile preview

FordPharma

East Windsor, New Jersey, United Stateszoominfo.com ↗

Ownership: Private
Development stage: Other

Overview

ForDoz Pharma develops, manufactures, and commercializes innovative complex injectable medicines. It has a proprietary particle-based drug delivery platform, a state-of-the-art cGMP sterile manufacturing facility, offers CDMO services to other companies, and received its first FDA approval in July 2024 for Doxorubicin Hydrochloride liposomal injection. The company focuses on both generic and innovative long acting injectable products targeting severe/chronic diseases including cancer.

Therapeutic areas: Oncology
Modalities: Complex injectables (including liposomal formulations and long acting injectables)Particle-based drug delivery technologiesGeneric and 505(b)(2) products
Industry: Biotech

Partnerships

Not specifically listed. Company mentions working with commercial marketing/sales partners worldwide.

Beyond the preview

Go deeper on FordPharma.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on FordPharma.

Explore the full profile